J&J bites back against dengue, linking antiviral to protection from infection in challenge trial

One of the last drugs standing at Johnson & Johnson’s slimmed-down infectious disease unit has come through another test. The oral candidate, JNJ-1802, induced antiviral activity against dengue in a human challenge study, offering the Big Pharma encouragement as it works toward data in a larger community-based trial.